Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Benjamin Haaland, Akhil Chopra, Sanchalika Acharyya, André P Fay, Gilberto de Lima Lopes

ABSTRACT

BACKGROUND: Based on improved clinical outcomes in randomized controlled clinical trials (RCTs) the FDA and EMA have approved bevacizumab with interferon, sunitinib, and pazopanib in the first-line treatment of low to intermediate risk metastatic clear cell renal cell carcinoma (mRCC). However, there is little comparative data to help in choosing the most effective drug among these agents. METHODS: We performed an indirect comparative effectiveness analysis of the pivotal RCTs of bevacizumab with interferon, sunitinib, or pazopanib compared to one another or interferon alone in first-line treatment of metastatic or advanced RCC. Endpoints of interest were overall survival (OS), progression free survival (PFS), and response rate (RR). Adverse events were also examined. RESULTS: The meta-estimate of the hazard ratio (95% confidence interval) for OS for bevacizumab with interferon vs. interferon alone was 0.86 (0.76-0.97), for sunitinib vs. interferon alone was 0.82 (0.67-1.00), for pazopanib vs. interferon alone was 0.74 (0.57-0.97), for sunitinib vs. bevacizumab with interferon was 0.95 (0.75-1.20), for pazopanib vs. bevacizumab with interferon was 0.86 (0.64-1.16), and for pazopanib vs. sunitinib was 0.91 (0.76-1.08). Similarly, bevacizumab with interferon, sunitinib, or pazopanib had better PFS and RR than interferon alone. Sunitinib and pazopanib had better RR than bevacizumab with interferon and there was suggestive evidence pazopanib may outperform sunitinib in terms of RR. CONCLUSIONS: Bevacizumab with interferon, sunitinib, and pazopanib are adequate first-line options in treatment of mRCC. Interferon alone should not be considered an optimal first-line treatment. More... »

PAGES

592

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-14-592

DOI

http://dx.doi.org/10.1186/1471-2407-14-592

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020918770

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25127891


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferons", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National University of Singapore", 
          "id": "https://www.grid.ac/institutes/grid.4280.e", 
          "name": [
            "Centre for Quantitative Medicine, Office of Clinical Sciences, Duke-National University of Singapore Graduate Medical School, 8 College Road, 169857, Singapore, Singapore", 
            "Department of Statistics and Applied Probability, National University of Singapore, Science Drive 2, 117546, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haaland", 
        "givenName": "Benjamin", 
        "id": "sg:person.01214037112.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214037112.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Johns Hopkins Singapore International Medical Center, Jalan Tan Tock Seng, 308433, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chopra", 
        "givenName": "Akhil", 
        "id": "sg:person.013023566251.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013023566251.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke NUS Graduate Medical School", 
          "id": "https://www.grid.ac/institutes/grid.428397.3", 
          "name": [
            "Centre for Quantitative Medicine, Office of Clinical Sciences, Duke-National University of Singapore Graduate Medical School, 8 College Road, 169857, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Acharyya", 
        "givenName": "Sanchalika", 
        "id": "sg:person.01162374137.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162374137.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana\u2013Farber Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Post-Graduate Program - School of Medicine, Pontificia Universidade Catolica do Rio Grande do Sul, Av. Ipiranga, 6681 - Partenon, 90619-900, Porto Alegre, RS, Brazil", 
            "Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, 450 Brookline Ave, 02215-5450, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fay", 
        "givenName": "Andr\u00e9 P", 
        "id": "sg:person.0625023535.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625023535.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Johns Hopkins University", 
          "id": "https://www.grid.ac/institutes/grid.21107.35", 
          "name": [
            "Oncoclinicas do Brasil, Avenida Barbacena 472-14\u00b0 andar, Belo Horizonte, MG, Brazil", 
            "Hospital do Cora\u00e7\u00e3o Cancer Center (HCor Onco), S\u00e3o Paulo, Brazil", 
            "Johns Hopkins University, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lopes", 
        "givenName": "Gilberto de Lima", 
        "id": "sg:person.01363174124.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363174124.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0090-4295(99)80079-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000386810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.hoc.2011.06.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000903601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.hoc.2011.04.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003587804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.37.1195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003613275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.1187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005415550"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/02841869009126537", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007301603"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834010361470", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009152728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834010361470", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009152728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61904-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010511397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-9-34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011234840", 
          "https://doi.org/10.1186/1471-2407-9-34"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11591410-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012210710", 
          "https://doi.org/10.2165/11591410-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.7849", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012958075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.1293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013684571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.3342", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015052000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2011.51", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016700441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0000000000000156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017817967"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018020219", 
          "https://doi.org/10.1038/sj.onc.1203938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018020219", 
          "https://doi.org/10.1038/sj.onc.1203938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020803009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-010-0901-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025376", 
          "https://doi.org/10.1007/s00432-010-0901-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-010-0901-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025376", 
          "https://doi.org/10.1007/s00432-010-0901-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-010-0901-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025376", 
          "https://doi.org/10.1007/s00432-010-0901-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra0706596", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021959499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.06.132", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022235480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)03544-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024732734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.46.4891", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025795239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2008.05.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027278641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.molcel.2008.04.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029492922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1303989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030656737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0094-0143(03)00056-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033053451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11596-011-0680-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033383716", 
          "https://doi.org/10.1007/s11596-011-0680-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(86)90046-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034546744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(86)90046-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034546744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2012.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037544552"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61874-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037964214"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.5561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038804231"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199609193351207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041427269"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.9847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041483211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70465-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043448950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cgc.2005.n.030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043681253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70124-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046924268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.1186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047418980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.50.8267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053397983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000658-199809000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060134855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000658-199809000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060134855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000658-199809000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060134855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074251883", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.9.2859", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549920"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.14694/edbook_am.2012.32.299", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078845868"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "BACKGROUND: Based on improved clinical outcomes in randomized controlled clinical trials (RCTs) the FDA and EMA have approved bevacizumab with interferon, sunitinib, and pazopanib in the first-line treatment of low to intermediate risk metastatic clear cell renal cell carcinoma (mRCC). However, there is little comparative data to help in choosing the most effective drug among these agents.\nMETHODS: We performed an indirect comparative effectiveness analysis of the pivotal RCTs of bevacizumab with interferon, sunitinib, or pazopanib compared to one another or interferon alone in first-line treatment of metastatic or advanced RCC. Endpoints of interest were overall survival (OS), progression free survival (PFS), and response rate (RR). Adverse events were also examined.\nRESULTS: The meta-estimate of the hazard ratio (95% confidence interval) for OS for bevacizumab with interferon vs. interferon alone was 0.86 (0.76-0.97), for sunitinib vs. interferon alone was 0.82 (0.67-1.00), for pazopanib vs. interferon alone was 0.74 (0.57-0.97), for sunitinib vs. bevacizumab with interferon was 0.95 (0.75-1.20), for pazopanib vs. bevacizumab with interferon was 0.86 (0.64-1.16), and for pazopanib vs. sunitinib was 0.91 (0.76-1.08). Similarly, bevacizumab with interferon, sunitinib, or pazopanib had better PFS and RR than interferon alone. Sunitinib and pazopanib had better RR than bevacizumab with interferon and there was suggestive evidence pazopanib may outperform sunitinib in terms of RR.\nCONCLUSIONS: Bevacizumab with interferon, sunitinib, and pazopanib are adequate first-line options in treatment of mRCC. Interferon alone should not be considered an optimal first-line treatment.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2407-14-592", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma", 
    "pagination": "592", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "63ab6ab871a071bf8ebc536938a43bcf26cd22a99e8ffdea4849a6081cfd06f1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25127891"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-14-592"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020918770"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-14-592", 
      "https://app.dimensions.ai/details/publication/pub.1020918770"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T01:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8697_00000550.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1471-2407-14-592"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-592'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-592'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-592'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-592'


 

This table displays all metadata directly associated to this object as RDF triples.

321 TRIPLES      21 PREDICATES      92 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-14-592 schema:about N128496359cc34bfd94b3d0cecd9aa7b2
2 N176077b7444f463d82eefe852120d89b
3 N1ae5c68857614e6497bd9e318becaec0
4 N3c0c81b3c2224eb5bcd4a90fd5717267
5 N417eaf0102c04f74a940e6e55959814f
6 N489a2b13034e415fa4144dc9280b0477
7 N6760436ce0834075b942f50e05174acb
8 N6d1b417f2c074e5ea8b0a19e6211188b
9 N8b583d70fc3645bd8f82b39a4d8b89b4
10 N9955fa0c4cea49adb1036172d2524c50
11 Nc213d338fa6d4ad3ba9e05f3c406bdc6
12 Nc4e3b4b932454b6897155a3f93bdc8b8
13 Ncb940bad3019436dae82b4e3f382ea2b
14 Neb08e2baae994706a713d9c34e7f76d2
15 Nebd3501d8c7648fcaaebdbb945df0a60
16 Nfb87ade01567487dbdcfb0dad893af40
17 Nfffb35ffbf7f453e83454a13efabfbdd
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N0346c57681bb4d29bf687889be2754fc
21 schema:citation sg:pub.10.1007/s00432-010-0901-0
22 sg:pub.10.1007/s11596-011-0680-0
23 sg:pub.10.1038/sj.onc.1203938
24 sg:pub.10.1186/1471-2407-9-34
25 sg:pub.10.2165/11591410-000000000-00000
26 https://app.dimensions.ai/details/publication/pub.1074251883
27 https://doi.org/10.1001/jama.2011.51
28 https://doi.org/10.1002/sim.1186
29 https://doi.org/10.1002/sim.1187
30 https://doi.org/10.1016/0197-2456(86)90046-2
31 https://doi.org/10.1016/j.ejca.2012.12.010
32 https://doi.org/10.1016/j.hoc.2011.04.004
33 https://doi.org/10.1016/j.hoc.2011.06.001
34 https://doi.org/10.1016/j.juro.2008.05.015
35 https://doi.org/10.1016/j.molcel.2008.04.009
36 https://doi.org/10.1016/s0090-4295(99)80079-x
37 https://doi.org/10.1016/s0094-0143(03)00056-9
38 https://doi.org/10.1016/s0140-6736(07)61874-1
39 https://doi.org/10.1016/s0140-6736(07)61904-7
40 https://doi.org/10.1016/s0140-6736(98)03544-2
41 https://doi.org/10.1016/s1470-2045(11)70124-3
42 https://doi.org/10.1016/s1470-2045(13)70465-0
43 https://doi.org/10.1056/nejm199609193351207
44 https://doi.org/10.1056/nejmoa021491
45 https://doi.org/10.1056/nejmoa060655
46 https://doi.org/10.1056/nejmoa065044
47 https://doi.org/10.1056/nejmoa1303989
48 https://doi.org/10.1056/nejmra0706596
49 https://doi.org/10.1097/00000658-199809000-00004
50 https://doi.org/10.1097/jto.0000000000000156
51 https://doi.org/10.1177/1758834010361470
52 https://doi.org/10.1200/jco.1999.17.8.2530
53 https://doi.org/10.1200/jco.1999.17.9.2859
54 https://doi.org/10.1200/jco.2004.06.132
55 https://doi.org/10.1200/jco.2008.16.9847
56 https://doi.org/10.1200/jco.2008.19.3342
57 https://doi.org/10.1200/jco.2008.20.1293
58 https://doi.org/10.1200/jco.2009.23.9764
59 https://doi.org/10.1200/jco.2009.26.5561
60 https://doi.org/10.1200/jco.2009.26.7849
61 https://doi.org/10.1200/jco.2011.37.1195
62 https://doi.org/10.1200/jco.2012.46.4891
63 https://doi.org/10.1200/jco.2013.50.8267
64 https://doi.org/10.14694/edbook_am.2012.32.299
65 https://doi.org/10.3109/02841869009126537
66 https://doi.org/10.3816/cgc.2005.n.030
67 schema:datePublished 2014-12
68 schema:datePublishedReg 2014-12-01
69 schema:description BACKGROUND: Based on improved clinical outcomes in randomized controlled clinical trials (RCTs) the FDA and EMA have approved bevacizumab with interferon, sunitinib, and pazopanib in the first-line treatment of low to intermediate risk metastatic clear cell renal cell carcinoma (mRCC). However, there is little comparative data to help in choosing the most effective drug among these agents. METHODS: We performed an indirect comparative effectiveness analysis of the pivotal RCTs of bevacizumab with interferon, sunitinib, or pazopanib compared to one another or interferon alone in first-line treatment of metastatic or advanced RCC. Endpoints of interest were overall survival (OS), progression free survival (PFS), and response rate (RR). Adverse events were also examined. RESULTS: The meta-estimate of the hazard ratio (95% confidence interval) for OS for bevacizumab with interferon vs. interferon alone was 0.86 (0.76-0.97), for sunitinib vs. interferon alone was 0.82 (0.67-1.00), for pazopanib vs. interferon alone was 0.74 (0.57-0.97), for sunitinib vs. bevacizumab with interferon was 0.95 (0.75-1.20), for pazopanib vs. bevacizumab with interferon was 0.86 (0.64-1.16), and for pazopanib vs. sunitinib was 0.91 (0.76-1.08). Similarly, bevacizumab with interferon, sunitinib, or pazopanib had better PFS and RR than interferon alone. Sunitinib and pazopanib had better RR than bevacizumab with interferon and there was suggestive evidence pazopanib may outperform sunitinib in terms of RR. CONCLUSIONS: Bevacizumab with interferon, sunitinib, and pazopanib are adequate first-line options in treatment of mRCC. Interferon alone should not be considered an optimal first-line treatment.
70 schema:genre research_article
71 schema:inLanguage en
72 schema:isAccessibleForFree true
73 schema:isPartOf N74fa2eb5d95c4a07ac526ab991621899
74 N882826f318f44cb4a18cf3da911f989f
75 sg:journal.1024632
76 schema:name Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
77 schema:pagination 592
78 schema:productId N3a79082932b344e1816b613f4d24fcde
79 N47316c24065841228cf038270893327b
80 N5176b0e2e8b444ca956af5196bb953cb
81 Nc663660c87f1483fbdb28c44ff0a90c8
82 Ncdae381f447c4369b170fe207bef9224
83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020918770
84 https://doi.org/10.1186/1471-2407-14-592
85 schema:sdDatePublished 2019-04-11T01:14
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher Ne939691693cd4ff6a499228538915e51
88 schema:url http://link.springer.com/10.1186%2F1471-2407-14-592
89 sgo:license sg:explorer/license/
90 sgo:sdDataset articles
91 rdf:type schema:ScholarlyArticle
92 N01aa423dff4c44718efe05271d08f964 rdf:first sg:person.01363174124.43
93 rdf:rest rdf:nil
94 N0346c57681bb4d29bf687889be2754fc rdf:first sg:person.01214037112.64
95 rdf:rest N080ffc958d214cf98a6c0f4c2eadcb1e
96 N080ffc958d214cf98a6c0f4c2eadcb1e rdf:first sg:person.013023566251.41
97 rdf:rest Nb335f0662c294a3194c3a1fe7f386469
98 N128496359cc34bfd94b3d0cecd9aa7b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Sulfonamides
100 rdf:type schema:DefinedTerm
101 N176077b7444f463d82eefe852120d89b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Antineoplastic Agents
103 rdf:type schema:DefinedTerm
104 N1ae5c68857614e6497bd9e318becaec0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Neoplasm Metastasis
106 rdf:type schema:DefinedTerm
107 N3a79082932b344e1816b613f4d24fcde schema:name readcube_id
108 schema:value 63ab6ab871a071bf8ebc536938a43bcf26cd22a99e8ffdea4849a6081cfd06f1
109 rdf:type schema:PropertyValue
110 N3c0c81b3c2224eb5bcd4a90fd5717267 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Kidney Neoplasms
112 rdf:type schema:DefinedTerm
113 N412a359f24674413ab1d4964388f5692 rdf:first sg:person.0625023535.16
114 rdf:rest N01aa423dff4c44718efe05271d08f964
115 N417eaf0102c04f74a940e6e55959814f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Interferons
117 rdf:type schema:DefinedTerm
118 N47316c24065841228cf038270893327b schema:name nlm_unique_id
119 schema:value 100967800
120 rdf:type schema:PropertyValue
121 N489a2b13034e415fa4144dc9280b0477 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Pyrimidines
123 rdf:type schema:DefinedTerm
124 N5176b0e2e8b444ca956af5196bb953cb schema:name dimensions_id
125 schema:value pub.1020918770
126 rdf:type schema:PropertyValue
127 N6760436ce0834075b942f50e05174acb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Antineoplastic Combined Chemotherapy Protocols
129 rdf:type schema:DefinedTerm
130 N6d1b417f2c074e5ea8b0a19e6211188b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Pyrroles
132 rdf:type schema:DefinedTerm
133 N74fa2eb5d95c4a07ac526ab991621899 schema:issueNumber 1
134 rdf:type schema:PublicationIssue
135 N882826f318f44cb4a18cf3da911f989f schema:volumeNumber 14
136 rdf:type schema:PublicationVolume
137 N8b583d70fc3645bd8f82b39a4d8b89b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Angiogenesis Inhibitors
139 rdf:type schema:DefinedTerm
140 N9955fa0c4cea49adb1036172d2524c50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Randomized Controlled Trials as Topic
142 rdf:type schema:DefinedTerm
143 Na93ee77841fc4e69b7ccbad3e649e201 schema:name Johns Hopkins Singapore International Medical Center, Jalan Tan Tock Seng, 308433, Singapore, Singapore
144 rdf:type schema:Organization
145 Nb335f0662c294a3194c3a1fe7f386469 rdf:first sg:person.01162374137.54
146 rdf:rest N412a359f24674413ab1d4964388f5692
147 Nc213d338fa6d4ad3ba9e05f3c406bdc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 Nc4e3b4b932454b6897155a3f93bdc8b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Indoles
152 rdf:type schema:DefinedTerm
153 Nc663660c87f1483fbdb28c44ff0a90c8 schema:name doi
154 schema:value 10.1186/1471-2407-14-592
155 rdf:type schema:PropertyValue
156 Ncb940bad3019436dae82b4e3f382ea2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Survival Analysis
158 rdf:type schema:DefinedTerm
159 Ncdae381f447c4369b170fe207bef9224 schema:name pubmed_id
160 schema:value 25127891
161 rdf:type schema:PropertyValue
162 Ne939691693cd4ff6a499228538915e51 schema:name Springer Nature - SN SciGraph project
163 rdf:type schema:Organization
164 Neb08e2baae994706a713d9c34e7f76d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Carcinoma, Renal Cell
166 rdf:type schema:DefinedTerm
167 Nebd3501d8c7648fcaaebdbb945df0a60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Molecular Targeted Therapy
169 rdf:type schema:DefinedTerm
170 Nfb87ade01567487dbdcfb0dad893af40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Bevacizumab
172 rdf:type schema:DefinedTerm
173 Nfffb35ffbf7f453e83454a13efabfbdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Antibodies, Monoclonal, Humanized
175 rdf:type schema:DefinedTerm
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
180 schema:name Clinical Sciences
181 rdf:type schema:DefinedTerm
182 sg:journal.1024632 schema:issn 1471-2407
183 schema:name BMC Cancer
184 rdf:type schema:Periodical
185 sg:person.01162374137.54 schema:affiliation https://www.grid.ac/institutes/grid.428397.3
186 schema:familyName Acharyya
187 schema:givenName Sanchalika
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162374137.54
189 rdf:type schema:Person
190 sg:person.01214037112.64 schema:affiliation https://www.grid.ac/institutes/grid.4280.e
191 schema:familyName Haaland
192 schema:givenName Benjamin
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214037112.64
194 rdf:type schema:Person
195 sg:person.013023566251.41 schema:affiliation Na93ee77841fc4e69b7ccbad3e649e201
196 schema:familyName Chopra
197 schema:givenName Akhil
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013023566251.41
199 rdf:type schema:Person
200 sg:person.01363174124.43 schema:affiliation https://www.grid.ac/institutes/grid.21107.35
201 schema:familyName Lopes
202 schema:givenName Gilberto de Lima
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363174124.43
204 rdf:type schema:Person
205 sg:person.0625023535.16 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
206 schema:familyName Fay
207 schema:givenName André P
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625023535.16
209 rdf:type schema:Person
210 sg:pub.10.1007/s00432-010-0901-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021025376
211 https://doi.org/10.1007/s00432-010-0901-0
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/s11596-011-0680-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033383716
214 https://doi.org/10.1007/s11596-011-0680-0
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/sj.onc.1203938 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018020219
217 https://doi.org/10.1038/sj.onc.1203938
218 rdf:type schema:CreativeWork
219 sg:pub.10.1186/1471-2407-9-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011234840
220 https://doi.org/10.1186/1471-2407-9-34
221 rdf:type schema:CreativeWork
222 sg:pub.10.2165/11591410-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012210710
223 https://doi.org/10.2165/11591410-000000000-00000
224 rdf:type schema:CreativeWork
225 https://app.dimensions.ai/details/publication/pub.1074251883 schema:CreativeWork
226 https://doi.org/10.1001/jama.2011.51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016700441
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1002/sim.1186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047418980
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1002/sim.1187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005415550
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1016/0197-2456(86)90046-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034546744
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1016/j.ejca.2012.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037544552
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1016/j.hoc.2011.04.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003587804
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1016/j.hoc.2011.06.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000903601
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1016/j.juro.2008.05.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027278641
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1016/j.molcel.2008.04.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029492922
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1016/s0090-4295(99)80079-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1000386810
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/s0094-0143(03)00056-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033053451
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/s0140-6736(07)61874-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037964214
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/s0140-6736(07)61904-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010511397
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1016/s0140-6736(98)03544-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024732734
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/s1470-2045(11)70124-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046924268
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1016/s1470-2045(13)70465-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043448950
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1056/nejm199609193351207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041427269
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1056/nejmoa021491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020803009
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1056/nejmoa1303989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030656737
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1056/nejmra0706596 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021959499
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1097/00000658-199809000-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060134855
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1097/jto.0000000000000156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017817967
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1177/1758834010361470 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009152728
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1200/jco.1999.17.8.2530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549876
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1200/jco.1999.17.9.2859 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549920
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1200/jco.2004.06.132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022235480
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1200/jco.2008.16.9847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041483211
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1200/jco.2008.19.3342 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015052000
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1200/jco.2008.20.1293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013684571
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1200/jco.2009.26.5561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038804231
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1200/jco.2009.26.7849 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012958075
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1200/jco.2011.37.1195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003613275
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1200/jco.2012.46.4891 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025795239
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1200/jco.2013.50.8267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053397983
299 rdf:type schema:CreativeWork
300 https://doi.org/10.14694/edbook_am.2012.32.299 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078845868
301 rdf:type schema:CreativeWork
302 https://doi.org/10.3109/02841869009126537 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007301603
303 rdf:type schema:CreativeWork
304 https://doi.org/10.3816/cgc.2005.n.030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043681253
305 rdf:type schema:CreativeWork
306 https://www.grid.ac/institutes/grid.21107.35 schema:alternateName Johns Hopkins University
307 schema:name Hospital do Coração Cancer Center (HCor Onco), São Paulo, Brazil
308 Johns Hopkins University, Baltimore, MD, USA
309 Oncoclinicas do Brasil, Avenida Barbacena 472-14° andar, Belo Horizonte, MG, Brazil
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.4280.e schema:alternateName National University of Singapore
312 schema:name Centre for Quantitative Medicine, Office of Clinical Sciences, Duke-National University of Singapore Graduate Medical School, 8 College Road, 169857, Singapore, Singapore
313 Department of Statistics and Applied Probability, National University of Singapore, Science Drive 2, 117546, Singapore, Singapore
314 rdf:type schema:Organization
315 https://www.grid.ac/institutes/grid.428397.3 schema:alternateName Duke NUS Graduate Medical School
316 schema:name Centre for Quantitative Medicine, Office of Clinical Sciences, Duke-National University of Singapore Graduate Medical School, 8 College Road, 169857, Singapore, Singapore
317 rdf:type schema:Organization
318 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
319 schema:name Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, 450 Brookline Ave, 02215-5450, Boston, MA, USA
320 Post-Graduate Program - School of Medicine, Pontificia Universidade Catolica do Rio Grande do Sul, Av. Ipiranga, 6681 - Partenon, 90619-900, Porto Alegre, RS, Brazil
321 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...